Evidence map›Paper›PMID 29100346›Full record

ArticleOncotarget2017

Inhibition of HIV-1 infection in humanized mice and metabolic stability of protein phosphatase-1-targeting small molecule 1E7-03.

Xionghao Lin, Namita Kumari, Catherine DeMarino, Yasemin Saygideğer Kont, Tatiana Ammosova, Amol Kulkarni, Marina Jerebtsova, Guelaguetza Vazquez-Meves, Andrey Ivanov, Kovalskyy Dmytro and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Xionghao LinCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Namita KumariCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Catherine DeMarinoLaboratory of Molecular Virology, George Mason University, Manassas, VA, USA.
Yasemin Saygideğer KontLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Tatiana AmmosovaCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Amol KulkarniDepartment of Pharmaceutical Sciences, College of Pharmacy, Howard University, Washington, DC, USA.
Marina JerebtsovaDepartment of Microbiology, College of Medicine, Howard University, Washington, DC, USA.
Guelaguetza Vazquez-MevesCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Andrey IvanovCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Kovalskyy DmytroDepartment of Biochemistry, University of Texas Health Science Center, San Antonio, TX, USA.
Aykut ÜrenLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Fatah KashanchiLaboratory of Molecular Virology, George Mason University, Manassas, VA, USA.
Sergei NekhaiCenter for Sickle Cell Disease, College of Medicine, Howard University, Washington, DC, USA.
Howard University · USGeorge Mason University · USGeorgetown University · USThe University of Texas Health Science Center at San Antonio · US

Funding

SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI MICHAEL Ilya BUKRINSKY · 2015 to 2026
$29.6M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
Georgetown-Howard Universities Center for Clinical and Translational Science (GHUUL1TR000101 · NCATS · GEORGETOWN UNIVERSITY · PI MELLMAN, THOMAS A, VERBALIS, JOSEPH G · 2012 to 2015
$19.3M
Therapeutics Targeting Filoviral interferon-antagonist and replication functionsU19AI109664 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$15.8M
PROTEOMICS CORE FACILITYG12MD007597 · NIMHD · HOWARD UNIVERSITY · PI SOUTHERLAND, WILLIAM M. · 2012 to 2018
$14.8M
Center for Hemoglobin Research in Minorities (CHaRM)P50HL118006 · NHLBI · HOWARD UNIVERSITY · PI NEKHAI, SERGEI · 2013 to 2017
$7.0M
Sickle Cell Disease and Sickle Cell Trait Protection Against HIV-1-infection in Africans and African AmericansR01HL125005 · NHLBI · HOWARD UNIVERSITY · PI MARINA A JEREBTSOVA, SERGEI NEKHAI · 2014 to 2026
$6.7M
HIV1 INHIBITION USING TAT PEPTIDE DERIVATIVESR01AI043894 · NIAID · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI KASHANCHI, FATAH · 1999 to 2015
$4.4M
HIV-1 TAR derived miRNA: Implications for Latency and PathogenesisR21AI078859 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI KASHANCHI, FATAH · 2009 to 2010
$400k
NCATS NIH HHS UL1 TR000101NHLBI NIH HHS P50 HL118006NHLBI NIH HHS R01 HL125005NIAID NIH HHS P30 AI117970NIAID NIH HHS R01 AI043894NIAID NIH HHS R21 AI078859NIAID NIH HHS U19 AI109664NIAID NIH HHS UM1 AI126617NIMHD NIH HHS G12 MD007597
6 · The paper itself

Abstract

We recently identified the protein phosphatase-1 - targeting compound, 1E7-03 which inhibited HIV-1

Indexed as

HIV-1HIV-1 infected humanized micemetabolic stabilityprotein phosphatase-1small molecule HIV-1 inhibitor

Identifiers

PMID29100346
PMCPMC5652740
OpenAlexW2743121708

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.